Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lantern Pharma ( (LTRN) ) has issued an announcement.
On January 22, 2026, Lantern Pharma hosted an event where it used a prepared presentation to support discussions and a live demonstration of its initial AI tools and multi-agent system designed for rare cancer applications. The event, and the associated presentation, underscored the company’s operational focus on integrating advanced AI technologies into oncology research for rare cancers, signaling continued efforts to position itself as a technology-driven player in precision cancer therapeutics and to engage stakeholders around its emerging AI platform capabilities.
The most recent analyst rating on (LTRN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
The score is held back primarily by weak financial performance (no revenue, persistent losses, and significant cash burn), which elevates financing/runway risk. Offsetting this, the earnings call conveyed meaningful pipeline and regulatory progress plus RADR commercialization momentum. Technicals remain soft (below major moving averages), while valuation metrics are constrained by negative earnings and no indicated dividend.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma operates in the biotechnology and pharmaceutical sector, focusing on the development and application of artificial intelligence tools, including multi-agent systems, aimed at advancing treatments for rare cancers.
Average Trading Volume: 75,930
Technical Sentiment Signal: Sell
Current Market Cap: $40.15M
Find detailed analytics on LTRN stock on TipRanks’ Stock Analysis page.